Investor Relations

Investors

Investor Relations

Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. sd-rxRNA therapeutics can be used as a standalone treatment or in combination with other modalities.